Guney-Coskun M, Basaranoglu M. Interplay of gut microbiota, glucagon-like peptide receptor agonists, and nutrition: New frontiers in metabolic dysfunction-associated steatotic liver disease therapy. World J Gastroenterol 2024; 30(43): 4682-4688 [DOI: 10.3748/wjg.v30.i43.4682]
Corresponding Author of This Article
Merve Guney-Coskun, BSc, MSc, Lecturer, Department of Nutrition and Dietetics, Faculty of Health Sciences, Istanbul Medipol University, Kavacık, Göztepe Mah, No. 40 Atatürk Cd, Istanbul 34810, Türkiye. merve.guney@medipol.edu.tr
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Letter to the Editor
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastroenterol. Nov 21, 2024; 30(43): 4682-4688 Published online Nov 21, 2024. doi: 10.3748/wjg.v30.i43.4682
Interplay of gut microbiota, glucagon-like peptide receptor agonists, and nutrition: New frontiers in metabolic dysfunction-associated steatotic liver disease therapy
Merve Guney-Coskun, Metin Basaranoglu
Merve Guney-Coskun, Department of Nutrition and Dietetics, Faculty of Health Sciences, Istanbul Medipol University, Istanbul 34810, Türkiye
Merve Guney-Coskun, Department of Nutrition and Dietetics, Graduate School of Health Sciences, Istanbul Medipol University, Istanbul 34810, Türkiye
Metin Basaranoglu, Department of Gastroenterology and Hepatology, Faculty of Medicine, Bezmialem Vakif University, Istanbul 34093, Türkiye
Author contributions: Guney-Coskun M and Basaranoglu M contributed to this editorial; Guney-Coskun M conceptualized the manuscript and outlined the overall structure; Basaranoglu M provided critical input to the discussion and design of the content; Both authors contributed to the writing, editing, literature review, and final approval of the manuscript.
Conflict-of-interest statement: All authors confirm that they have no personal, financial, or professional conflicts of interest.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Merve Guney-Coskun, BSc, MSc, Lecturer, Department of Nutrition and Dietetics, Faculty of Health Sciences, Istanbul Medipol University, Kavacık, Göztepe Mah, No. 40 Atatürk Cd, Istanbul 34810, Türkiye. merve.guney@medipol.edu.tr
Received: August 20, 2024 Revised: September 20, 2024 Accepted: October 14, 2024 Published online: November 21, 2024 Processing time: 72 Days and 14.3 Hours
Abstract
The gut-liver axis plays a crucial role in the development and progression of metabolic dysfunction-associated steatotic liver disease (MASLD). Key metabolites, including lipopolysaccharides, short-chain fatty acids (SCFAs), bile acids, and beneficial gut bacteria such as Bifidobacterium and Lactobacillus, are pivotal in this process. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) show promise in managing MASLD by promoting weight loss, enhancing insulin secretion, and improving liver health. They restore gut-liver axis functionality, and their effects are amplified through dietary modifications and gut microbiome-targeted therapies. Emerging research highlights the interplay between GLP-1 RAs and gut microbiota, indicating that the gut microbiome significantly influences therapeutic outcomes. Metabolites produced by gut bacteria, can stimulate glucagon-like peptide-1 (GLP-1) secretion, further improving metabolic health. Integrating dietary interventions with GLP-1 RA treatment may enhance liver health by modulating the gut microbiota-SCFAs-GLP-1 pathway. Future research is needed to understand personalized effects, with prebiotics and probiotics offering treatment avenues for MASLD.
Core Tip: The gut-liver axis is integral in the progression of various diseases, with key metabolites like lipopolysaccharides, short-chain fatty acids, bile acids, immune factors, inflammatory cytokines, and beneficial bacteria such as Bifidobacterium and Lactobacillus playing pivotal roles. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) contribute to substantial weight loss, enhance insulin secretion, reduce appetite, and improve liver health by restoring gut-liver axis functionality. Dietary modifications can amplify these benefits, while gut microbiome-targeted therapies may offer additional advantages in treating metabolic dysfunction-associated steatotic liver disease. Future multi-omics research will underscore the importance of personalized GLP-1 RAs treatment considering gut microbiota effects, with prebiotics and probiotics potentially improving liver health via the gut microbiota.
